Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Shitara, Kohei; Van Cutsem, Eric; Bang, Yung‐Jue; S. Fuchs, Charles; Wyrwicz, Lucjan; Lee, Keun‐Wook; Kudaba, Iveta; Garrido, Marcelo; Cheol Chung, Hyun; Lee, Jeeyun; R. Castro, Hugo; Mansoor, Wasat; Ignez Braghiroli, Maria; Karaseva, Nina; Caglevic, Christian; J. Villanueva-Rivera, Luis; Goekkurt, Eray; Satake, Hironaga; C. Enzinger, Peter; Alsina, María; B. Benson, Al; Chao, Joseph; H. Ko, Andrew; A. Wainberg, Zev; Kher, Uma; Shah, Sukrut; Peter Kang, Soonmo; Tabernero, Josep

doi:10.1001/jamaoncol.2020.3370

Public

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Published in JAMA Oncology • Sep 3, 2020

Authors:

Kohei Shitara

Eric Van Cutsem

Yung‐Jue Bang

Abstract

Importance: Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. Objective: To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with untreated, advanced G/GEJ ca...

Subject

Pembrolizumab

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!